We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+12.1%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.3B
AUM Growth
+$892M
Cap. Flow
+$30.9M
Cap. Flow %
0.25%
Top 10 Hldgs %
85.9%
Holding
130
New
9
Increased
23
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$33.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$17.1M
3
ONC
BeOne Medicines Ltd
ONC
+$16.8M
4
SAGE
Sage Therapeutics
SAGE
+$15.5M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.5M

Top Sells

Rank Stock Value
1
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$22.1M
2
AKAO
Achaogen Inc
AKAO
+$17.5M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.3M
4
BLUE
bluebird bio
BLUE
+$6.47M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 93.01%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.5B
$4B 32.41%
34,230,323
+100,162
+0.3% +$12.7M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$2.49B 20.18%
45,725,556
– –
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$1.2B 9.73%
8,553,864
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.43B
$973M 7.89%
25,819,768
– –
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$12B
$550M 4.46%
5,905,673
– –
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$442M 3.59%
13,780,480
+614
+0% +$19.4K
ONC
7
BeOne Medicines Ltd
ONC
$33.9B
$403M 3.27%
3,898,431
+225,256
+6% +$16.8M
DBVT
8
DBV Technologies
DBVT
$800M
$234M 1.9%
550,956
– –
NGNE icon
9
Neurogene
NGNE
$646M
$155M 1.26%
546,708
– –
AAAP
10
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$152M 1.23%
2,243,262
+21,556
+1% +$1.05M
ONCE
11
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$123M 1%
1,384,130
+65,789
+5% +$5M
ASND icon
12
Ascendis Pharma A/S
ASND
$16.7B
$85.1M 0.69%
2,348,840
+597,377
+34% +$17.1M
AMRN
13
Amarin Corp
AMRN
$299M
$79.3M 0.64%
1,133,475
– –
AVXS
14
DELISTED
AveXis, Inc. Common Stock
AVXS
$75M 0.61%
775,000
+150,000
+24% +$13.5M
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$2.43B
$73.3M 0.59%
13,997,172
+2,280,388
+19% +$11.7M
NVTA
16
DELISTED
Invitae Corporation
NVTA
$68.3M 0.55%
7,288,300
– –
ARRY
17
DELISTED
Array Biopharma Inc
ARRY
$64.1M 0.52%
5,213,528
+3,627,615
+229% +$33.7M
AKAO
18
DELISTED
Achaogen Inc
AKAO
$62M 0.5%
3,886,878
-917,726
-19% -$17.5M
BLCM
19
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$58.1M 0.47%
503,231
– –
EXEL icon
20
Exelixis
EXEL
$14B
$50.4M 0.41%
2,082,012
– –
HRTX icon
21
Heron Therapeutics
HRTX
$91.6M
$45M 0.37%
2,787,992
+4,423
+0.2% +$69.4K
NBIX icon
22
Neurocrine Biosciences
NBIX
$18.2B
$37.8M 0.31%
616,682
– –
BLUE
23
DELISTED
bluebird bio
BLUE
$33.2M 0.27%
18,639
-4,632
-20% -$6.47M
SGMO
24
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$31.7M 0.26%
2,113,376
-2,000,000
-49% -$22.1M
ABEO icon
25
Abeona Therapeutics
ABEO
$343M
$28.7M 0.23%
67,375
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Baker Bros. Advisors held 130 positions worth $12.3B, up 7.8% from $11.4B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2017 filing shows 9 new, 23 increased, 9 reduced and 9 closed positions. Its largest new stake was Acorda Therapeutics: 4,329 shares worth $12.3M. The largest sale was SANGAMO THERAPEUTICS INC, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q3 2017 buy was Acorda Therapeutics: 4,329 shares worth $12.3M.
  • Baker Bros. Advisors added most to Array Biopharma Inc in Q3 2017, an estimated $33.7M increase.
  • Baker Bros. Advisors's biggest Q3 2017 reduction was SANGAMO THERAPEUTICS INC, cutting an estimated $22.1M.
  • Baker Bros. Advisors fully exited Zogenix, Inc. in Q3 2017, selling an estimated $2.69M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $12.3B portfolio in Q3 2017.
  • Baker Bros. Advisors opened 9 new positions and closed 9 in Q3 2017.
  • Baker Bros. Advisors's portfolio value rose 7.8% quarter-over-quarter to $12.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.